GB201817354D0 - Engineered FC - Google Patents

Engineered FC

Info

Publication number
GB201817354D0
GB201817354D0 GBGB1817354.2A GB201817354A GB201817354D0 GB 201817354 D0 GB201817354 D0 GB 201817354D0 GB 201817354 A GB201817354 A GB 201817354A GB 201817354 D0 GB201817354 D0 GB 201817354D0
Authority
GB
United Kingdom
Prior art keywords
engineered
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Ceased
Application number
GBGB1817354.2A
Other languages
English (en)
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Hummingbird Bioscience Holdings Ltd
Original Assignee
Hummingbird Bioscience Holdings Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Hummingbird Bioscience Holdings Ltd filed Critical Hummingbird Bioscience Holdings Ltd
Priority to GBGB1817354.2A priority Critical patent/GB201817354D0/en
Publication of GB201817354D0 publication Critical patent/GB201817354D0/en
Priority to CN201980070848.2A priority patent/CN112912393A/zh
Priority to TW108138679A priority patent/TW202031681A/zh
Priority to PCT/EP2019/079131 priority patent/WO2020084104A1/en
Priority to EP19801222.1A priority patent/EP3870605A1/en
Priority to US17/288,245 priority patent/US20210388083A1/en
Ceased legal-status Critical Current

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/2803—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily
    • C07K16/283—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily against Fc-receptors, e.g. CD16, CD32, CD64
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/32—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against translation products of oncogenes
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/52—Constant or Fc region; Isotype
    • C07K2317/524—CH2 domain
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/52—Constant or Fc region; Isotype
    • C07K2317/526—CH3 domain
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/72—Increased effector function due to an Fc-modification
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/73—Inducing cell death, e.g. apoptosis, necrosis or inhibition of cell proliferation
    • C07K2317/732—Antibody-dependent cellular cytotoxicity [ADCC]
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/90—Immunoglobulins specific features characterized by (pharmaco)kinetic aspects or by stability of the immunoglobulin
    • C07K2317/92—Affinity (KD), association rate (Ka), dissociation rate (Kd) or EC50 value
GBGB1817354.2A 2018-10-25 2018-10-25 Engineered FC Ceased GB201817354D0 (en)

Priority Applications (6)

Application Number Priority Date Filing Date Title
GBGB1817354.2A GB201817354D0 (en) 2018-10-25 2018-10-25 Engineered FC
CN201980070848.2A CN112912393A (zh) 2018-10-25 2019-10-25 工程化的fc
TW108138679A TW202031681A (zh) 2018-10-25 2019-10-25 經工程處理之Fc
PCT/EP2019/079131 WO2020084104A1 (en) 2018-10-25 2019-10-25 Engineered fc
EP19801222.1A EP3870605A1 (en) 2018-10-25 2019-10-25 Engineered fc
US17/288,245 US20210388083A1 (en) 2018-10-25 2019-10-25 Engineered fc

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
GBGB1817354.2A GB201817354D0 (en) 2018-10-25 2018-10-25 Engineered FC

Publications (1)

Publication Number Publication Date
GB201817354D0 true GB201817354D0 (en) 2018-12-12

Family

ID=64560497

Family Applications (1)

Application Number Title Priority Date Filing Date
GBGB1817354.2A Ceased GB201817354D0 (en) 2018-10-25 2018-10-25 Engineered FC

Country Status (6)

Country Link
US (1) US20210388083A1 (zh)
EP (1) EP3870605A1 (zh)
CN (1) CN112912393A (zh)
GB (1) GB201817354D0 (zh)
TW (1) TW202031681A (zh)
WO (1) WO2020084104A1 (zh)

Family Cites Families (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5731168A (en) 1995-03-01 1998-03-24 Genentech, Inc. Method for making heteromultimeric polypeptides
EP2471813B1 (en) * 2004-07-15 2014-12-31 Xencor, Inc. Optimized Fc variants
CN113480639A (zh) * 2012-02-09 2021-10-08 中外制药株式会社 抗体的Fc区变异体
EP3444278A1 (en) 2013-02-26 2019-02-20 Roche Glycart AG Bispecific t cell activating antigen binding molecules
EP3617317A4 (en) * 2017-02-17 2021-01-13 Xiamen University PEPTIDIC SUPPORT FOR THE DISPLAY OF A TARGET POLYPEPTIDE AND ASSOCIATED USE
WO2019185164A1 (en) * 2018-03-29 2019-10-03 Hummingbird Bioscience Holdings Pte. Ltd. Her3 antigen-binding molecules

Also Published As

Publication number Publication date
WO2020084104A1 (en) 2020-04-30
US20210388083A1 (en) 2021-12-16
EP3870605A1 (en) 2021-09-01
CN112912393A (zh) 2021-06-04
TW202031681A (zh) 2020-09-01

Similar Documents

Publication Publication Date Title
SG11202113253SA (en) Engineered casx systems
IL275426A (en) Transgenic FC fusion proteins containing IL-2
HK1257480A1 (zh) 工程病毒
IL282092B (en) Engineered enzymes
IL281950A (en) Transgenic genetic modulators
IL283849A (en) Proof of work for blockchain applications
GB201800761D0 (en) Interaction between blockchains
EP3635101A4 (en) MODIFIED LIGASE VARIANTS
GB2577682B (en) Auto-injector
IL279880A (en) Transgenic phosphopantomutase variant enzymes
EP3402879A4 (en) TECHNOLOGY LUBRICANT
GB2547884B (en) Follow focus
EP3515503A4 (en) MANIPULATED LYMPHOCYTES
GB201817831D0 (en) No title
SG11202105365RA (en) Modified fc region
GB2613719B (en) Engineered soil
CA204449S (en) Auto-injector
GB201817354D0 (en) Engineered FC
ZA201801475B (en) Engineered cry6a insecticidal proteins
GB201912198D0 (en) Engineered CRISPRa
GB201912179D0 (en) Engineered CRISPRa
IL264033A (en) Mop set
GB201808432D0 (en) Engineered Soil
ZAA201900401S (en) Icon
ZAA201900402S (en) Icon

Legal Events

Date Code Title Description
COOA Change in applicant's name or ownership of the application

Owner name: HUMMINGBIRD BIOSCIENCE HOLDINGS PTE. LTD.

Free format text: FORMER OWNER: HUMMINGBIRD BIOSCIENCE PTE. LTD

AT Applications terminated before publication under section 16(1)